Asset profile
SEP-380135
Small molecule
Evidence outlook · lead readout
NCT07549581 · Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07549581: Participants were randomized and both participants and investigators were kept unaware of treatment assignment against a placebo, but this is a small, short Phase 1 safety and dose-finding study across several psychiatric symptom scales rather than a trial powered to prove clinical benefit, and results are not yet posted.
Also in development:Schizophrenia · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.